Trial Profile
An Open-labelled, Randomised, Parallel Group, Multicentre, Safety and Efficacy Study of NN-X14Mix50 (BIAsp50) in a Twice Daily Regimen in Type 2 Diabetic Subjects.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Insulin aspart/insulin protamine aspart (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Novo Nordisk
- 23 Apr 2015 New trial record